alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-29-1997
<PERIOD-START>                             DEC-31-1996
<PERIOD-END>                               MAR-31-1997
<CASH>                                             329
<SECURITIES>                                         0
<RECEIVABLES>                                    3,640
<ALLOWANCES>                                         0
<INVENTORY>                                      2,900
<CURRENT-ASSETS>                                 9,393
<PP&E>                                         147,226
<DEPRECIATION>                                  55,355
<TOTAL-ASSETS>                                 144,976
<CURRENT-LIABILITIES>                           19,908
<BONDS>                                         40,794
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            99
<OTHER-SE>                                      80,598
<TOTAL-LIABILITY-AND-EQUITY>                   144,976
<SALES>                                         38,347
<TOTAL-REVENUES>                                38,347
<CGS>                                           11,828
<TOTAL-COSTS>                                   11,828
<OTHER-EXPENSES>                                21,823
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,181
<INCOME-PRETAX>                                    977
<INCOME-TAX>                                       303
<INCOME-CONTINUING>                                674
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       674
<EPS-PRIMARY>                                      .08
<EPS-DILUTED>                                      .08
        

</TABLE>
Exhibit 32.1



SECTION 906 CERTIFICATIONCEO



In connection with the Annual Report of Plains Exploration & Production Company (the Company) on Form 10-K/A for the period ending December 31, 2003
as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James C. Flores, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:



To the best of my knowledge, after
reasonable investigation:



| | (1) |  | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- |  | ---------------------------------------------------------------------------------------------------------------------



| | (2) |  | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| | --- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------



Dated: June 14, 2004.



/s/    James C. FloresJames C. Flores Chief Executive Officer






The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate
disclosure document.



A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be
retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
EX-4.3



 





Exhibit 4.3




CERTIFICATE OF TRUST




OF




NATIONAL CITY CAPITAL TRUST V




     THIS CERTIFICATE OF TRUST of NATIONAL CITY CAPITAL TRUST V (the “Trust”), dated as of November 5, 2007 is being duly executed and filed by the undersigned, as trustee, to form a statutory trust
under the Delaware Statutory Trust Act (12 Del. C. (Section) 3801 et seq.).



     1. NAME. The name of the statutory trust being formed hereby is National City Capital Trust V.



     2. DELAWARE TRUSTEE. The name and business address of the trustee of the Trust with a
principal place of business in the State of Delaware are as follows:



The Bank of New York (Delaware)

White Clay Center, Route 273

New Castle County

Newark, Delaware 19711

Attention: Corporate Trust




     3. EFFECTIVE DATE. This Certificate of Trust shall be effective upon filing.



     IN WITNESS WHEREOF, the undersigned, being the trustee of the Trust, has executed this
Certificate of Trust as of the date first above written.



	 	 	 	 	 
	 	THE BANK OF NEW YORK (DELAWARE)

Not in its individual capacity, but
solely as Delaware Trustee

 	 
	 	By:  	/s/ Kristine K. Gullo	 
	 	 	Name: Kristine K. Gullo	 
	 	 	Title: Vice President
Exhibit 31.1 CERTIFICATION I, Neil Leibman, Chief Executive
Officer of Gexa Corp., certify that: 1.
       I have reviewed this quarterly report on Form 10-Q of Gexa Corp.; 2.
Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to
the period covered by this report; 3.
Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in
this report; 4.
The registrants other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the registrant and have: (a)
      Designed such disclosure controls and procedures,  or caused such disclosure
 controls and procedures to be designed under our supervision,  to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which this
report is being prepared; (b)
      Evaluated the  effectiveness of the registrants  disclosure  controls and
procedures and presented in this report our conclusions  about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and (c)
      Disclosed in this report any change in the  registrants  internal  control
over financial  reporting  that occurred  during the  registrants  most recent
fiscal quarter that has materially affected, or is reasonably likely to materially
effect, the registrants internal control over financial reporting; and 5.
The registrants other certifying officers and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrants
auditors and the audit committee of the registrants board of directors (or persons
performing the equivalent functions): (a)
      All  significant  deficiencies  and material  weaknesses in the design or operation
of controls over financial  reporting  which are  reasonably  likely to adversely affect
the registrants ability to record, process, summarize and report financial
information; and (b)
      Any fraud,  whether or not material,  that involves  management or other employees
who have a significant  role in the  registrants  internal control over financial
reporting.  /s/ Neil Leibman 
Neil
LeibmanChief Executive OfficerDated: August 11, 2004
*December 18, 2014*

Dear Colleagues:

Although we are living in a time of unprecedented scientific opportunities, the funding climate has become increasingly challenging for researchers. In light of this issue, the NIH and its individual Institutes have begun considering a range of options to enhance research funding stability and flexibility. The proposals on the table are diverse. Institutes are considering using different funding mechanisms that target investigators at specific career stages. For example, some Institutes are designing programs for early-career stage investigators, while others are focusing their efforts on more senior scientists.

We, at the NIAMS, have decided to focus on early-established investigators (EEIs), those who have recently renewed their first R01 award. These individuals are most vulnerable, and are going to be offered an opportunity to broaden their project with funds that will encourage more innovation and the opportunity to move their project into a comprehensive program.

The goal of the program, called Supplements to Advance Research (STAR) Awards, is to promote innovation and exploration of new research directions. Ultimately, we believe that the awards will assist EEIs in making the transition from work on a single research project to leadership of a comprehensive research program. EEIs will be eligible for the award early after the renewal of their first R01, and candidates will be asked to express a vision for their research program and to explain its significance and potential impact. Candidates also will need to detail their plan for achieving their research goals. Institutions will be asked to contribute to the success of this effort by affirming a strong commitment to supporting the awardee’s research program.

The STAR program was developed with input from NIAMS staff, NIH colleagues, the extramural research community, and the NIAMS Advisory Council. We plan to launch the program in 2015 and will be reaching out to the community and the eligible investigators to raise awareness about this initiative. We are pleased to provide supplemental innovation funding to enable EEIs to build a research program. We expect that this will be a very important component of our ongoing efforts to support the biomedical research workforce and the development of the next generation of investigators. More information about the STAR initiative will be available in the NIH Guide in the coming months.

Stephen I. Katz, M.D., Ph.D.DirectorNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institutes of Health

12/18/2014

Back to Top
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2481 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2481

To suspend temporarily the duty on certain mold curing devices used in 
the manufacture of extra-wide pneumatic truck and automobile tires, and 
                     parts and accessories thereof.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            October 29, 2009

  Mr. Graham introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
To suspend temporarily the duty on certain mold curing devices used in 
the manufacture of extra-wide pneumatic truck and automobile tires, and 
                     parts and accessories thereof.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CERTAIN MOLD CURING DEVICES USED IN THE MANUFACTURE OF 
              EXTRA-WIDE PNEUMATIC TRUCK AND AUTOMOBILE TIRES, AND 
              PARTS AND ACCESSORIES THEREOF.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.01.00       Curing presses of   Free         No change        No change        On or before 12/ ''.
                          a kind used to                                                     31/2011.......
                          produce pneumatic
                          truck and
                          automobile tires
                          having a tread
                          width of at least
                          450 mm, such
                          presses together
                          with head of line
                          selection
                          equipment, and
                          parts thereof
                          (provided for in
                          subheadings
                          8477.51.00,
                          8477.90.25,
                          8477.90.65, or
                          8477.90.85)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
EXHIBIT
32.1





CERTIFICATION


PURSUANT
TO 18 U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of QuantRx Biomedical Corporation (the
"Company") on Form 10-Q for the period ending June 30, 2009 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Walter
Witoshkin, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002,
that to my knowledge:





1. The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





2. The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.






/s/
      Walter WitoshkinWalter
      WitoshkinChairman
      & CEO


Date: August
14, 2009




A signed
original of this written statement required by Section 906 has been provided to
the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.
**EXHIBIT 32.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER(pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18U.S.C.§1350))**

Pursuant to Section 906of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), the undersigned, GordonLink, Senior Vice President and Chief Financial Officer of TapestryPharmaceuticals, Inc. (the “Company”) does hereby certify, to hisknowledge, that:

(a)          the Annual Report on Form 10-Kfor the fiscal year ended December 28, 2005 of the Company (the “Report”)fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934, and

(b)         theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

Date: February 22,2006

|            |       | /s/  GORDON LINK                                   |
|------------|------------|----------------------------------------------------|
|       | ** ** | Gordon Link                                        |
| ** ** | ** ** | Senior Vice  President and Chief Financial Officer |

 

A signed original of this written statement requiredby Section 906 has been provided to Tapestry Pharmaceuticals, Inc.and will be retained by Tapestry Pharmaceuticals, Inc. and furnished tothe Securities and Exchange Commission or its staff upon request. Thiscertification “accompanies” the Form 10-K to which it relates, isnot deemed filed with the SEC and is not to be incorporated by reference intoany filing of the Company under the Securities Act of 1933, as amended, or theSecurities Exchange Act of 1934, as amended (whether made before or after thedate of the Form 10-K), irrespective of any general incorporationlanguage contained in such filing.

----
<PAGE>                                  

                                  EXHIBIT 15

To the Shareholders and Board of Directors
 of Sears, Roebuck and Co.
 
We have made a review, in accordance with standards established by the 
American Institute of Certified Public Accountants, of the unaudited 
interim financial information of Sears, Roebuck and Co. for the 13- week 
periods ended July 4, 1998 and June 28, 1997, as indicated in our report 
dated August 14, 1998; because we did not perform an audit, we expressed 
no opinion on that information.

We are aware that our report referred to above, which is included in your 
Quarterly Report on Form 10-Q for the 13-week period ended July 4, 1998, is 
incorporated by reference in Registration Statement Nos. 2-64879, 2-80037, 
33-18081, 33-23793, 33-41485, 33-43459, 33-45479, 33-55825, 33-58851, 
33-64345, 333-8141 and 333-38131 of Sears, Roebuck and Co.; Registration 
Statement Nos. 33-58139, 333-9817, 33-64215 and 333-30879 of Sears, Roebuck 
and Co. and Sears Roebuck Acceptance Corp.; Registration Statement Nos. 
33-64775, 333-18591, and 333-43309 of Sears, Roebuck and Co. and Sears, 
Roebuck and Co. Deferred Compensation Plan; Registration Statement Nos.
33-57205, 333-11973 and 333-53149, of Sears, Roebuck and Co. and the Sears 
401(k) Profit Sharing Plan (formerly, The Savings and Profit Sharing Fund 
of Sears Employees); and Registration Statement No. 33-44671 of Sears, 
Roebuck and Co. and Sears DC Corp.

We are also aware that the aforementioned report, pursuant to Rule 436(c) 
under the Securities Act of 1933, is not considered a part of the Registration
Statement prepared or certified by an accountant or a report prepared or 
certified by an accountant within the meaning of Sections 7 and 11 of that 
Act.



Deloitte & Touche LLP

Chicago, Illinois
August 14, 1998
Exhibit
32.2





CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of NeoStem, Inc. (the “Company”) on Form
10-Q for the period ended September 30, 2010  filed with the
Securities and Exchange Commission on the date hereof (the “Report”), I, Larry
A. May, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that, to my knowledge:





(1)
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934 as amended ;
  and








(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition of the Company as of the dates presented
      and the results of operations of the Company for the periods
      presented.





Dated:  November
12, 2010





/s/
      Larry A. MayLarry
      A. MayChief
      Financial Officer





The
foregoing certification is being furnished solely pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63
of Title 18, United States Code) and is not being filed as part of the Form 10-Q
or as a separate disclosure document.





A signed
original of this written statement required by Section 906 has been provided to
NeoStem, Inc. and will be retained by NeoStem, Inc. and furnished to the
Securities and Exchange Commission or its staff upon request.
IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 19
- 0706 IN THE MATTER OF: N.A., Respondent and Appellant . **ORDER** Upon consideration of Appellant’s motion for extension of time, and good cause appearing, IT IS HEREBY ORDERED that Appellant is granted an extension of time to and including September 28 , 2020 , within which to prepare, file, and serve Appellant’s opening brief on appeal.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

August 25 2020

08/25/2020

Case Number: DA 19-0706
FOR IMMEDIATE RELEASE No. 2024-01

January 11, 2024

Contact

Media Relations

Phone: (571) 557-5450

Email: mediarelations@nga.mil

NGA announces $290M Luno A commercial data RFP

SPRINGFIELD, Virginia – The National Geospatial-Intelligence Agency is soliciting proposals 

for Luno A, a $290 million indefinite delivery, indefinite quantity contract to acquire unclassified

commercial GEOINT-derived computer vision and analytic service capabilities. This will be a 

five-year IDIQ with awards to multiple vendors, focused on monitoring global economic and 

environmental activity and military capabilities.

Luno A is a follow-on to the Economic Indicator Monitoring contract, which focused on 

managing the deluge of data by purchasing commercial data as services to integrate with NGA 

machine learning and artificial intelligence efforts. Luno A will expand access to data and 

services for the National System for Geospatial Intelligence, accelerate analytic workflow 

modernization objectives and integrate data and services into enterprise capabilities.

“Because of the incredible success with the EIM contract, we’ve substantially increased our 

financial commitment to commercial capabilities with Luno A,” said Devin Brande, director of 

NGA Commercial Operations. “As the quantity and quality of commercial data continues to 

increase, we must continue to partner effectively with industry to keep pace with state-of-the-art

analytic capabilities and meet the increasing demands of our customers.”

Luno A will deliver data that enables NGA and NSG analysts to add context to analytic 

assessments, and have unparalleled insight into and data to quantify worldwide economic and 

environmental activity and military capabilities. The unclassified nature of commercial data will 

ensure that Luno A products, data, and/or services are easily shareable with key partners and 

allies across the globe.

Luno A will focus on identifying unclassified computer vision capabilities, to include object 

detection, object classification, object segmentation, pattern detection, broad area search and

area monitoring and feature mapping across six areas of interest: 

• General change detection, climate security and natural resources.

• Feature identification.

• Infrastructure and high cadence transportation network monitoring.

• Facility monitoring.

• Incidental and fortuitous processing.

• Emerging products, data and services.
You can find more information about Luno A at SAM.gov or the Acquisition Research Center.

# # #

About NGA

NGA delivers world-class geospatial intelligence that provides a decisive advantage to policymakers, 

warfighters, intelligence professionals and first responders.

NGA is a unique combination of intelligence agency and combat support agency. It is the world leader in 

timely, relevant, accurate and actionable geospatial intelligence. NGA enables the U.S. intelligence 

community and the Department of Defense to fulfill the president’s national security priorities to protect 

the nation.

For more information about NGA, visit us online at nga.mil, Instagram, LinkedIn, Facebook and X/Twitter.